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identified	 56	 outcomes	 for	 adjusted	 analyses.	 Adjustment	 identified	 12	 showing	
independent	 associations	with	 paracetamol	 use	 at	P	 <	 .05,	 four	 of	which	were	 at	
P	<	.0001	(all	related	to	child	behaviours	reported	by	the	mother	at	42	and	47	months;	
eg	 conduct	 problems:	 adjusted	mean	 score	 +	 0.22	 (95%	 confidence	 interval	 0.10,	















This	 is	 particularly	 (but	 not	 exclusively)	 true	 of	 over‐the‐counter	
medications,	currently	the	most	common	of	which	is	paracetamol.
In	general,	despite	evidence	that	paracetamol	crosses	the	pla‐
centa2	and	 is	a	known	endocrine	disruptor3	and	a	COX	 inhibitor,4 
the	medical	 profession	 is	 relatively	 relaxed	 about	 the	 use	 of	 this	
analgesic	 in	 pregnancy;	 it	 is	 usually	 claimed	 to	 be	 the	 analgesic	
of	 choice.	 It	 is	 true	 that	 it	 has	 not	 been	 implicated	 in	major	mal‐













Because	 it	 is	 so	 common,	 and	no	 links	with	 congenital	malfor‐
mations	have	been	made,	paracetamol	 is	 considered	 the	analgesic	
of	 choice	 for	 pregnant	women.19	 It	 is	 commonly	 taken	 in	 Europe,	
with	estimates	of	 fetal	exposure	 from	over	40%	of	pregnancies	 in	
Spain,9	 55%	 in	Denmark7	 to	 65%	 in	 France.20	When	 assessing	 ef‐
fects	 of	 prenatal	 exposures	 to	 the	 child	with	 a	 neurocognitive	 or	




collected	 longitudinally,	 starting	 in	pregnancy.	This	we	do	here	by	
analysing	 information	collected	by	 the	Avon	Longitudinal	Study	of	
Parents	 and	 Children	 (ALSPAC).	 First,	 we	 determined	 the	 factors	
that	were	independently	associated	with	the	intake	of	paracetamol	
using	an	exposome	technique,21	and	then	taking	these	factors	into	
account,	 we	 determined	 independent	 associations	 with	 cognitive	
and	behavioural	outcomes	of	the	offspring.
2  | METHODS
Pregnant	 women	 who	 were	 resident	 in	 Avon,	 UK	 with	 expected	
dates	of	delivery	between	1st	April	1991	and	31st	December	1992	
were	invited	to	take	part	in	the	Avon	Longitudinal	Study	of	Parents	
and	Children	 (ALSPAC).22‐24	The	 initial	 number	of	pregnancies	en‐
rolled	was	 14	 541	 (for	 these	 at	 least	 one	 questionnaire	 had	 been	
returned).	Of	 these	 initial	 pregnancies,	 14	 150	 reached	 32	weeks	
(391	 having	 miscarried,	 been	 terminated	 or	 delivered	 before	 this	
gestation).	Questionnaires	sent	out	at	this	stage	 included	 informa‐
tion	on	paracetamol	intake,	and	were	returned	by	12	418	(88%)	of	
It	 is	 important	 that	 these	 results	be	 tested	using	other	datasets	or	methodologies	
before	assuming	that	they	are	causal.








Previous	 epidemiological	 studies	 concerning	 possible	



















and	 Law	 Committee	 and	 the	 Local	 Research	 Ethics	 Committees	
(ALEC;	IRB00003312)	(registered	on	the	Office	of	Human	Research	
Protections	database	as	U	Bristol	IRB	#1).	Informed	consent	for	the	
use	 of	 data	 collected	 via	 questionnaires	 and	 clinics	 was	 obtained	





Women	 in	 the	 study	 were	 sent	 a	 questionnaire	 entitled	 ‘Your	
Pregnancy’	at	about	32	weeks	gestation.	Of	the	14	150	women	in	
the	study,	12	418	(88%)	returned	the	questionnaire,	and	12	025	of	
these	 replied	 to	 the	 question	 on	 paracetamol	 use.	Data	were	 not	
available	for	women	who	had	delivered	prior	to	32	weeks	gestation,	
and	 those	 few	who	did	not	enrol	 in	 the	study	until	after	 the	baby	
was	born.
The	questions	asked	were:	‘Please indicate how often you have taken 
the following pills in the last three months’. (a) Aspirin; (b) Paracetamol; 
(c) Codeine; (d) Mogadon or other sleeping tablets; (e) Valium or other 
tranquilliser.	Possible	responses	were	as	follows:	everyday; most days; 









offspring,	 including	 biological	markers,	 physiological	 and	 psychiat‐
ric	tests	as	well	as	details	of	many	neurocognitive	measures.	In	this	
paper,	we	have	chosen	to	study	two	of	the	domains	most	mentioned	
in	 the	 literature	 and	 summarised	 in	 the	 introduction:	measures	 of	
cognition	and	behaviour.	We	have	tested	the	hypotheses	that	par‐
acetamol	taken	in	the	period	between	18	and	32	weeks	of	pregnancy	
Measure Age No. of tests
No. of tests (%) 
at P < .001
Cognitive	tests
IQ36 8	y 6 5	(83)
15	y 6 6	(100)
Memory37 8	y 2 0
10 y 2 0
17 y 2 0
Temperament
Carey	temperament26,27 6	mo 10 5	(50)
24	mo 10 5	(50)
EAS	temperament30 38	mo 4 1	(25)
Behaviour
Rutter31 42	mo 5 4	(80)
SDQ28	–	mother 47	mo 6 4	(67)
6	y 6 4	(67)
9 y 6 4	(67)
11 y 6 4	(67)
SDQ28	–	teacher 7‐8	y 6 1	(17)
10‐11 y 6 0
Feeding	difficulties 7 y 1 0
DAWBA29	outcomes
‐	Anxieties 7 y 10 2	(20)
‐	Compulsions 7 y 5 0
‐	Troublesome	behaviour 7 y 2 2	(100)
‐	Activity	&	attention 7 y 9 9	(100)
Selective	attention	tests38 8	y,	11	y 25 0
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increases	the	risk	of	behaviour	problems,	particularly	hyperactivity	
and	 conduct	 disorder,	 and	 we	 aim	 to	 determine	 the	 associations	
with	cognition,	having	no	prior	hypotheses.	We	have	excluded	from	
consideration	 at	 this	 point	 associations	 with	 educational	 abilities,	








the	 measure	 was	 obtained.	 Firstly,	 we	 considered	 cognitive	 tests	









haviour	 and	 of	 activity	 and	 attention	 as	 reported	 in	 the	 DAWBA	
set	of	questions29	administered	at	7	years.	 In	contrast,	 the	admin‐
istration	of	 the	TEACh	 tasks	of	 selective	attention	 showed	no	as‐
sociations,	in	contradiction	to	the	findings	of	the	Danish	study	of	a	
subsample	of	5‐year	olds.12
From	 these	 unadjusted	 analyses,	 we	 chose	 the	 following	 do‐












1.	 The	 identification	 of	 potential	 confounders	 used	 an	 exposome	
technique	 as	 developed	 earlier.21	 This	 involves:	 (a)	 identifying	
all	 factors	 that	were	 associated	 at	P	 <	 .0001	with	 paracetamol	
intake	at	32	weeks	gestation	 in	unadjusted	analyses,	 (b)	putting	
them	 into	 meaningful	 groups	 based	 on	 physical	 or	 psycholog‐
ical	 attributes,	 (c)	 within	 each	 group	 using	 step‐wise	 logistic	
regression	 to	 select	 those	 variables	 independently	 associated	
with	 taking	 the	 drug,	 (d)	 combining	 the	 variables	 identified	 as	
independent	 from	 each	 group	 with	 those	 from	 other	 groups,	
then	 use	 a	 step‐wise	 logistic	 regression	 to	 identify	 variables	
to	 include	 in	 a	 final	 model.	 The	 variables	 in	 this	 model	 will	
be	 those	 used	 as	 potential	 confounders.
2.	 Altogether	 135	 unadjusted	 relationships	 between	 paracetamol	















We	have	 not	modelled	 using	missing	 data	 techniques	 as	 the	 data	
are	 unlikely	 to	 be	 missing	 at	 random.	 The	 proportion	 of	 missing	





3.1 | Identification of potential confounders
As	noted	earlier,	43.9%	of	the	women	answering	the	questionnaire	







level	 (mother	had	 rheumatism	and	 social	 class	of	partner).	 The	35	
variables	were	divided	into	four	groups	(Table	S1):
a.	 background	 aspects	 of	 health	 (history	 of	 the	 following	 condi‐
tions:	 hay	 fever,	 asthma,	 indigestion,	 eczema,	 back	 pain,	 pelvic	
inflammatory	disease,	hypertension,	migraine,	severe	depression	
and	 rheumatism).
b.	 current	health	 in	the	period	18‐32	weeks	 (in	poor	health,	had	a	
cold,	had	‘flu,	had	an	infection,	had	a	headache,	had	backache,	high	
scores	 on	 anxiety,	malaise	 and	 depression	 scales	 at	 32	weeks).	
Since	there	was	no	obvious	category	for	body	mass	index	(BMI;	
weight	 (Kg)/height	 (m)2)	 pre‐pregnancy,	 it	 was	 included	 in	 this	
group.




























dietary	 pattern	 and	 of	 taking	 no	 alcohol	 during	 this	 time	 period.	
Interestingly,	 none	 of	 the	 traditional	 measures	 of	 socio‐economic	
status	were	retained	in	the	model.
The	 15	 variables	 were	 treated	 as	 possible	 confounders,	 since	
we	did	not	consider	it	warranted	to	carry	out	similar	modelling	pro‐
cedures	 for	 each	 of	 the	 56	 outcomes	 and	 thence	 identify	 factors	
predictive	of	both	paracetamol	intake	and	each	outcome.	The	con‐
founders	 identified	 in	 this	way	would	necessarily	 include	 some	of	
the	factors	predictive	of	paracetamol	intake.
3.2 | Availability of potential confounders
The	15	 variables	 comprising	 the	 final	 potential	 confounder	model	
were	 obtained	 from	 four	 different	 questionnaires	 administered	
Feature Took drug Did not take drug OR (95% CI) P
Medical	history
History	of	asthma 13.6% 9.9% 1.32	(1.15,	1.52) 1.0 × 10−4
History	of	
indigestion
75.7% 66.2% 1.19	(1.08,	1.32) 0.001
History	of	back	pain 52.6% 42.7% 1.11	(1.01,	1.22) 0.028
History	of	migraine 53.7% 36.5% 1.46	(1.33,	1.60) 5.4	×	10−16
Pre‐pregnancy	BMIa M	23.3 M	22.6 1.03	(1.02,	1.04) 8.0	×	10−6
In	period	18‐32	wk
In	poor	healthb 32.8% 18.8% 1.18	(1.12,	1.25) 8.0	×	10−9
Had	a	cold 48.5% 34.3% 1.44	(1.32,	1.59) 7.7 × 10−15
Had	‘flu 8.7% 3.8% 1.37	(1.10,	1.70) 0.005
Had	other	infection 7.1% 3.4% 1.33	(1.19,	1.49) 8.2	×	10−7
Had	a	headache 80.6% 46.4% 3.89	(3.52,	4.29) 5.5	×	10−160
Lifestyle
Healthy	diet	scorea M	‐	0.11 M	+	0.09 0.87	(0.83,	0.92) 2.4	×	10−8
Processed	diet	
scorea
M	+	0.07 M	‐	0.05 1.06	(1.01,	1.11) 0.014




M	11.4 M	10.5 1.02	(1.01,	1.03) 0.002







TA B L E  2  The	potential	confounders








information	 is	 available	 results	 in	 the	 loss	of	15%‐17%	of	 children	
concerning	the	scales	answered	by	the	parent	or	resulting	from	test‐
ing	in	the	ALSPAC	clinic	(eg	IQ	at	8)	and	20%	of	the	teacher	reports.










3.4 | Adjusted analyses for temperament variables
There	were	11	measures	of	the	child's	temperament	showing	a	sig‐












3.5 | Adjusted analyses for hyperactive behaviour
Measures	 of	 attention	 and	 excessive	 activity	 used	 the	 Strengths	








year	 3	was	 of	 borderline‐adjusted	 association	 (MD	 0.16	 (95%	CI	
−0.01,	+0.33)).	When	the	boys	and	girls	were	considered	separately	
(Table	 S5a,b),	 there	were	 similar	 significant	 adjusted	 associations	
for	 hyperactivity	 at	 ages	 42	 and	 47	 months,	 and	 for	 girls,	 the	
teacher	report	at	seven	was	also	significant	(Tables	4	and	5).























































































A	scale	for	 identification	of	conduct	problems	was	 included	 in	the	













Summation	 of	 the	 hyperactivity,	 conduct,	 peer	 and	 emotional	 dif‐
ficulty	 scales	 of	 the	 SDQ	was	 used	 to	 create	 a	 score	 of	 total	 be‐
havioural	difficulties.	Although	all	seven	measures	were	associated	
with	 maternal	 paracetamol	 intake	 in	 pregnancy,	 the	 associations	
were	 attenuated	 for	 all	 except	 the	 two	 early	 measures	 (Table	 3).	
Stratification	 by	 sex	 showed	 associations	 on	 adjustment	with	 the	
three	earliest	measures	for	boys,	and	the	42‐month	measure	for	girls	

























This	 is	 not	 the	 first	 time	 that	 fetal	 paracetamol	 exposure	 has	
been	 linked	 to	 hyperactivity,	 but	 it	 is	 probably	 the	 first	 time	 that	
the	potential	confounders	have	been	identified	using	an	exposome	
technique;	 this	 technique	 was	 hypothesis‐free,	 and	 thus	 likely	 to	
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identify	some	factors	that	had	not	previously	been	considered	to	be	
confounders.	One	other	study	has	used	the	ALSPAC	data	to	inves‐




taking	 the	 drug	 in	 the	 period	 18‐32	weeks	 and	 children	with	 the	
worst	 levels	 of	 hyperactivity,	 conduct	 disorder,	 emotionality	 and	
total	behaviour	difficulties.	Their	strategy	included	taking	a	number	
of	 confounders	 into	 account,	 but	 also	 assessing	whether	 paternal	
consumption	of	paracetamol,	or	intake	by	the	mother	5	years	later	
showed	 similar	 associations.11	 Our	 analysis	 also	 using	 these	 out‐
comes	at	81	months	showed	that	there	was	an	association	with	con‐












the	 review	was	 that	 ‘associations	were	strongest	 for	hyperactivity	
and	attention‐related	outcomes’.	This	supports	our	findings.














portant—rheumatism	 and	 social	 class;	 (c)	Division	 of	 these	 factors	
TA B L E  5  Among	sons,	mean	differences	in	outcome	measures	associated	with	paracetamol	exposure	at	18‐32	wk	gestation
Measure Na AMD (95% CI) Ptrend
Cognition
IQ:	Freedom	from	distractibility	at	8y 2722 −0.27	(−0.79,	+0.24) 0.249
Temperament
M.Adaptability	at	6m 4233 +0.44	(+0.06,	+0.82) 0.037
M.Approach	at	6m 4231 +0.44	(+0.03,	+0.86) 0.037
M.Distractibility	at	6m 4234 +0.40	(+0.02,	+0.78) 0.040
M.Difficult	baby	at	6m 4537 +1.35	(+0.15,	+2.54) 0.027
M.Persistence	at	24	m 4191 +0.36	(+0.03,	+0.69) 0.032
Behaviour
M.SDQ	Hyperactivity	at	42m 4068 +0.17	(+0.04,	+0.29) 0.010
M.SDQ	Hyperactivity	at	47m 3895 +0.19	(+0.03,	+0.36) 0.019
T.DAWBA	Attention	at	7‐8	y 2197 +0.29	(−0.24,	+0.81) 0.286
T.DAWBA	Attention/Activity	at	7‐8	y 2195 +0.34	(−0.49,	+1.16) 0.427
M.SDQ	Conduct	problems	at	42m 4068 +0.29	(+0.12,	+0.45) 0.001
M.SDQ	Conduct	problems	at	47m 3895 +0.10	(+0.00,	+0.20) 0.047
M.SDQ	Conduct	problems	at	81m 3476 +0.12	(+0.01,	+0.23) 0.027
M.SDQ	Conduct	problems	at	115m 3142 +0.12	(+0.01,	+0.24) 0.039
M.SDQ	Total	behavioural	difficultiesb	at	42m 4068 +0.61	(+0.21,	+1.00) 0.003
M.SDQ	Total	behavioural	difficultiesb	at	47m 3895 +0.35	(+0.03,	+0.67) 0.031
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into	 logical	 groups;	 (d)	 step‐wise	 logistic	 regression	 within	 each	
group;	 (e)	 combination	 of	 the	 results	 from	 the	 groups	 to	 create	 a	
final	 model	 containing	 15	 variables	 with	 a	 pseudo‐R2	 of	 14.35%.	
Interestingly,	the	modelling	exercise	(which	was	carried	out	using	a	
hypothesis‐free	approach)	rejected	many	of	the	features	that	were	














It	 is	 noteworthy	 that	 the	 literature	 review	 of	 Bauer	 and	 col‐
leagues35	 did	 not	 find	 results	 of	 neurocognitive	 associations	with	
prenatal	 paracetamol	 intake	 beyond	 the	 age	 of	 7.	 In	 the	 present	
study,	 we	 have	 shown	 that	 the	 strongest	 relationships	 with	 child	
behaviour	were	 identified	at	42	and	47	months,	and	that	the	SDQ	







4.2 | Strengths of the study
















test	 results	were	not	 related	 to	maternal	paracetamol	 intake.	This	
may,	however,	be	a	function	of	the	cognitive	test	rather	than	reveal‐
ing	a	defect	in	the	design.
4.3 | Limitations of the data
There	are	a	number	of	limitations.	(a)	Although	we	took	time	to	inves‐
tigate	possible	confounders	using	an	exposome	technique,	the	results	
are	necessarily	confined	 to	 the	 information	collected.	There	may	be	
many	other	features	that	should	have	been	adjusted	for	(residual	con‐
founding),	 and	 which	may	 change	 the	 conclusions	 of	 the	 paper.	 (b)	
Relevant	to	this	is	the	fact	that	we	used	a	very	statistically	stringent	



























ALSPAC	 team,	which	 includes	 interviewers,	 computer	 and	 labora‐
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